These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38920591)

  • 1. Design and Characterization of a Dual-Protein Strategy for an Early-Stage Assay of Ovarian Cancer Biomarker Lysophosphatidic Acid.
    Davoudian K; Spagnolo S; Lotay N; Satkauskas M; Mészáros G; Hianik T; Keresztes Z; Walker G; Thompson M
    Biosensors (Basel); 2024 Jun; 14(6):. PubMed ID: 38920591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coupled Electrostatic and Hydrophobic Destabilisation of the Gelsolin-Actin Complex Enables Facile Detection of Ovarian Cancer Biomarker Lysophosphatidic Acid.
    Davoudian K; Bhattacharya S; Thompson D; Thompson M
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of the Ovarian Cancer Biomarker Lysophosphatidic Acid in Serum.
    De La Franier B; Thompson M
    Biosensors (Basel); 2020 Feb; 10(2):. PubMed ID: 32075013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity-based electrochemical biosensor with antifouling properties for detection of lysophosphatidic acid, a promising early-stage ovarian cancer biomarker.
    Ahmadi S; Lotay N; Thompson M
    Bioelectrochemistry; 2023 Oct; 153():108466. PubMed ID: 37244204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gelsolin and functionally similar actin-binding proteins are regulated by lysophosphatidic acid.
    Meerschaert K; De Corte V; De Ville Y; Vandekerckhove J; Gettemans J
    EMBO J; 1998 Oct; 17(20):5923-32. PubMed ID: 9774337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis.
    Cao L; Zhang Y; Fu Z; Dong L; Yang S; Meng W; Li Y; Zhang W; Zhang J; Zheng C; Zhu H; Fan L
    J Obstet Gynaecol Res; 2015 Dec; 41(12):1951-8. PubMed ID: 26472266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical detection of lysophosphatidic acid: A new window for ovarian cancer diagnostics.
    Huang X; Feng B; Liu M; Liu Z; Li S; Zeng W
    Talanta; 2022 Sep; 247():123561. PubMed ID: 35609485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Near-Infrared Fluorogenic Probes with Polarity-Sensitive Emission for in Vivo Imaging of an Ovarian Cancer Biomarker.
    Yao D; Lin Z; Wu J
    ACS Appl Mater Interfaces; 2016 Mar; 8(9):5847-56. PubMed ID: 26910257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidic acid: an ovarian cancer marker.
    Sedláková I; Vávrová J; Tosner J; Hanousek L
    Eur J Gynaecol Oncol; 2008; 29(5):511-4. PubMed ID: 19051824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gelsolin binding and cellular presentation of lysophosphatidic acid.
    Goetzl EJ; Lee H; Azuma T; Stossel TP; Turck CW; Karliner JS
    J Biol Chem; 2000 May; 275(19):14573-8. PubMed ID: 10799543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
    Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
    JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Tailoring of Electrostatic and Hydrophobic Interactions for Rapid and Specific Recognition of Lysophosphatidic Acid, an Early-Stage Ovarian Cancer Biomarker.
    Wang Y; Pei H; Jia Y; Liu J; Li Z; Ai K; Lu Z; Lu L
    J Am Chem Soc; 2017 Aug; 139(33):11616-11621. PubMed ID: 28782946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dually Crosslinked Supramolecular Hydrogel for Cancer Biomarker Sensing.
    Li J; Ji C; Lü B; Rodin M; Paradies J; Yin M; Kuckling D
    ACS Appl Mater Interfaces; 2020 Aug; 12(33):36873-36881. PubMed ID: 32701258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.
    Mills GB; Eder A; Fang X; Hasegawa Y; Mao M; Lu Y; Tanyi J; Tabassam FH; Wiener J; Lapushin R; Yu S; Parrott JA; Compton T; Tribley W; Fishman D; Stack MS; Gaudette D; Jaffe R; Furui T; Aoki J; Erickson JR
    Cancer Treat Res; 2002; 107():259-83. PubMed ID: 11775454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
    Tanyi J; Rigó J
    Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lysophosphatidic acid in ovarian cancer patients].
    Sedlákova I; Vávrová J; Tosner J; Hanousek L
    Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
    Sedláková I; Vávrová J; Tošner J; Hanousek L
    Tumour Biol; 2011 Apr; 32(2):311-6. PubMed ID: 21061112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer.
    Meleh M; Pozlep B; Mlakar A; Meden-Vrtovec H; Zupancic-Kralj L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):287-91. PubMed ID: 17766199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis.
    Li YY; Zhang WC; Zhang JL; Zheng CJ; Zhu H; Yu HM; Fan LM
    Lipids Health Dis; 2015 Jul; 14():72. PubMed ID: 26174150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early stage detection and screening of ovarian cancer: A research opportunity and significant challenge for biosensor technology.
    Franier B; Thompson M
    Biosens Bioelectron; 2019 Jun; 135():71-81. PubMed ID: 31003031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.